Janus kinase (JAK) inhibitors in rheumatoid arthritis

Kunihiro Yamaoka, Yoshiya Tanaka

Research output: Contribution to journalArticle

Abstract

Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalCurrent Rheumatology Reviews
Volume7
Issue number4
DOIs
Publication statusPublished - 2011 Nov
Externally publishedYes

Fingerprint

Janus Kinases
Rheumatoid Arthritis
Biological Factors
Phosphotransferases
Clinical Trials
Antirheumatic Agents
Biological Products
Interleukin-6
Therapeutics
Tumor Necrosis Factor-alpha
Cytokines

Keywords

  • Janus kinase
  • Kinase inhibitor
  • Rheumatoid arthritis
  • Tofacitinib

ASJC Scopus subject areas

  • Rheumatology

Cite this

Janus kinase (JAK) inhibitors in rheumatoid arthritis. / Yamaoka, Kunihiro; Tanaka, Yoshiya.

In: Current Rheumatology Reviews, Vol. 7, No. 4, 11.2011, p. 306-312.

Research output: Contribution to journalArticle

Yamaoka, Kunihiro ; Tanaka, Yoshiya. / Janus kinase (JAK) inhibitors in rheumatoid arthritis. In: Current Rheumatology Reviews. 2011 ; Vol. 7, No. 4. pp. 306-312.
@article{82a8cfa5a447433298f2e39b5c55ef15,
title = "Janus kinase (JAK) inhibitors in rheumatoid arthritis",
abstract = "Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30{\%} of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.",
keywords = "Janus kinase, Kinase inhibitor, Rheumatoid arthritis, Tofacitinib",
author = "Kunihiro Yamaoka and Yoshiya Tanaka",
year = "2011",
month = "11",
doi = "10.2174/157339711798221086",
language = "English",
volume = "7",
pages = "306--312",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Janus kinase (JAK) inhibitors in rheumatoid arthritis

AU - Yamaoka, Kunihiro

AU - Tanaka, Yoshiya

PY - 2011/11

Y1 - 2011/11

N2 - Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.

AB - Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.

KW - Janus kinase

KW - Kinase inhibitor

KW - Rheumatoid arthritis

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=82255170445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255170445&partnerID=8YFLogxK

U2 - 10.2174/157339711798221086

DO - 10.2174/157339711798221086

M3 - Article

VL - 7

SP - 306

EP - 312

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 4

ER -